<DOC>
	<DOCNO>NCT01643434</DOCNO>
	<brief_summary>Resistant hypertension ( ReHy ) emerge clinical public health problem tend increase population live longer grow global epidemic obesity , diabetes sleep apnea . It also tempt speculate excessive dietary salt ingestion report many country contribute substantially risk ReHy development . ReHy define persistent high blood pressure ( target goal ) spite use least 3 antihypertensive agent different class , one must diuretics . Data regard exact prevalence ReHy limit . In addition , little data available 3-drug combination simplify treatment algorithm demonstrate combination diuretic plus angiotensin-converting enzyme inhibitor ( ACEi ) angiotensin-receptor blocker ( ARB ) plus diuretic , add calcium channel blocker necessary , control 64 % hypertensive patient , addition , even efficient current guideline-based management . By contrast , fourth drug added-on triple regimen still controversial guide empirical choice personal preference . Recent study suggest emerge role spironolactone `` first-line '' fourth drug treat resistant hypertension . Conversely , pathophysiological rationale , others propose use β-blockers even centrally act agent manage sympathetic hyperactivity . The present concern limit blood pressure reduce effect β-blockers , especially elderly people , potent effect centrally act agent personal experience point clonidine fourth drug added-on multidrug combination reach optimal blood pressure patient ReHy . Nevertheless , study perform compare , head-to-head , one best fourth drug ( spironolactone clonidine ) added-on common use multidrug combination order treat condition . Therefore , principal objective ReHOT Trial ass prospectively : ( 1 ) prevalence ReHy cohort outpatient stage II hypertension ; ( 2 ) effect spironolactone blood pressure , comparison clonidine , add multidrug combination consist chlorthalidone plus ACEi ( ARB ) plus amlodipine , 3 up-titrated high dose ; ( 3 ) role measure sympathetic nervous system activity renin-angiotensin-aldosterone activity predict response blood pressure spironolactone clonidine .</brief_summary>
	<brief_title>Resistant Hypertension Optimal Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients age 18 75 2 . With systolic blood pressure &gt; 160 mmHg &lt; 220mmHg / diastolic &gt; 100 mmHg sit position accord Brazilian Guidelines Hypertension ( perform step obtain two consecutive measurement differ less 4 mmHg , calibrate use sphygmomanometer ) 3 . Patient regularly enrol participate center Exclusion criterion 1 . Systolic blood pressure &gt; 220 mmHg 2 . Patients cardiovascular event ( stroke , AMI , etc. ) . cardiovascular procedure le 6 month evolution 3 . Renal stage IV V ( glomerular20 filtration estimate MDRD formula &lt; 30 ml / min ; MDRD = 186 x ( S_Cr ) 1.154 x ( age ) 0.203 x ( 0.742 fem . ) x ( 1.210 Afroamer . ) ) 4 . Heart failure class III IV 5 . History malignant disease life expectancy &lt; 2 year 6 . Alcoholism 7 . Psychiatric illness prevent compliance Protocol 8 . Women childbearing age use effective contraception 9 . Pregnancy 10 . Arrhythmias , valvular heart disease , AV block 2 3 degree without MP 11 . Hepatic impairment 12 . Patients history hypersensitivity drug study 13 . Examination fundus : Grade III Grade IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Resistant Hypertension</keyword>
</DOC>